Every engagement looks different, but the goal is always the same: help clients expand patient access and protect product value. The case studies below explore how we’ve helped life sciences leaders make faster, smarter decisions when it mattered most.
.png)
Tested and refined value propositions directly with U.S. payers to inform pricing, evidence priorities, and market access strategy ahead of launch.
.png)
Defined an early payer value story and evidence roadmap to prioritize Phase III data generation and strengthen market access readiness ahead of launch.
.png)
Helped a large diagnostics company prioritize evidence generation to strengthen its value narrative and support adoption amid increasing payer scrutiny.
.png)
Rapidly assessed the surgical complications landscape to help a large medtech company prioritize unmet needs and focus its early-stage innovation pipeline.
Supported a private equity investment decision by assessing EU reimbursement dynamics, pricing outlook, and volume trends for a diagnostics portfolio across key markets.
Supported a mid-size biotech in responding to emerging real-world evidence that favored a competitor by clarifying methodological limitations, shaping the evidence narrative, and protecting long-term access and positioning.
Centralized local access insights into a single, usable system to reduce duplication, accelerate launch readiness, and enable consistent payer strategies across markets.
.png)
Developed a forward-looking value framework to help a biotech align clinical development and evidence generation with evolving payer expectations in obesity.
.png)
Clarified patient segmentation and value drivers to reduce early uncertainty and guide product planning and market access strategy.
.png)
Built a payer-ready clinical and economic value case to support U.S. coverage discussions and accelerate reimbursement decisions for an innovative medical device.
.png)
Established a clear, evidence-based value narrative to support payer coverage discussions and enable access for a novel cardiac device.
.png)
Clarified and aligned the evidence base across stakeholders to support consistent value communication and accelerate adoption in an insured market.
.png)
Validated a new market opportunity by clarifying patient segmentation, unmet need, and economic dynamics to support early investment and development decisions.
.png)
Developed a clear, evidence-based value narrative to support payer discussions and strengthen coverage decisions across a diagnostic portfolio.
.png)
Validated how decision-makers evaluate new diagnostic tests, clarified what evidence would drive adoption, and informed a focused strategy to support uptake at launch.
Tested and refined value propositions directly with U.S. payers to inform pricing, evidence priorities, and market access strategy ahead of launch.
.png)
Defined an early value story and evidence generation roadmap to guide clinical, HEOR, and commercial planning for a rare disease therapy under an accelerated timeline.
.png)
Aligned global and local teams to anticipate HTA challenges early, clarify disease burden and value expectations, and reduce reimbursement risk ahead of launch in HTA-driven markets.
Tested and refined value propositions directly with U.S. payers to inform pricing, evidence priorities, and market access strategy ahead of launch.
Validated how decision-makers evaluate new diagnostic tests, clarified what evidence would drive adoption, and informed a focused strategy to support uptake at launch.
Tested and refined value propositions directly with U.S. payers to inform pricing, evidence priorities, and market access strategy ahead of launch.
Built a payer-ready clinical and economic value case to support U.S. coverage discussions and accelerate reimbursement decisions for an innovative medical device.
Established a clear, evidence-based value narrative to support payer coverage discussions and enable access for a novel cardiac device.
Clarified and aligned the evidence base across stakeholders to support consistent value communication and accelerate adoption in an insured market.
Helped a large diagnostics company prioritize evidence generation to strengthen its value narrative and support adoption amid increasing payer scrutiny.
Supported a private equity investment decision by assessing EU reimbursement dynamics, pricing outlook, and volume trends for a diagnostics portfolio across key markets.
Supported a mid-size biotech in responding to emerging real-world evidence that favored a competitor by clarifying methodological limitations, shaping the evidence narrative, and protecting long-term access and positioning.
Clarified patient segmentation and value drivers to reduce early uncertainty and guide product planning and market access strategy.
Built a payer-ready clinical and economic value case to support U.S. coverage discussions and accelerate reimbursement decisions for an innovative medical device.
Established a clear, evidence-based value narrative to support payer coverage discussions and enable access for a novel cardiac device.
Validated a new market opportunity by clarifying patient segmentation, unmet need, and economic dynamics to support early investment and development decisions.
Validated how decision-makers evaluate new diagnostic tests, clarified what evidence would drive adoption, and informed a focused strategy to support uptake at launch.
Defined an early value story and evidence generation roadmap to guide clinical, HEOR, and commercial planning for a rare disease therapy under an accelerated timeline.
Aligned global and local teams to anticipate HTA challenges early, clarify disease burden and value expectations, and reduce reimbursement risk ahead of launch in HTA-driven markets.
Built a payer-ready clinical and economic value case to support U.S. coverage discussions and accelerate reimbursement decisions for an innovative medical device.
Clarified patient segmentation and value drivers to reduce early uncertainty and guide product planning and market access strategy.
Validated a new market opportunity by clarifying patient segmentation, unmet need, and economic dynamics to support early investment and development decisions.
Tested and refined value propositions directly with U.S. payers to inform pricing, evidence priorities, and market access strategy ahead of launch.
Defined an early payer value story and evidence roadmap to prioritize Phase III data generation and strengthen market access readiness ahead of launch.
Helped a large diagnostics company prioritize evidence generation to strengthen its value narrative and support adoption amid increasing payer scrutiny.
Rapidly assessed the surgical complications landscape to help a large medtech company prioritize unmet needs and focus its early-stage innovation pipeline.
Centralized local access insights into a single, usable system to reduce duplication, accelerate launch readiness, and enable consistent payer strategies across markets.
Developed a forward-looking value framework to help a biotech align clinical development and evidence generation with evolving payer expectations in obesity.
Built a payer-ready clinical and economic value case to support U.S. coverage discussions and accelerate reimbursement decisions for an innovative medical device.
Established a clear, evidence-based value narrative to support payer coverage discussions and enable access for a novel cardiac device.
Clarified and aligned the evidence base across stakeholders to support consistent value communication and accelerate adoption in an insured market.
Developed a clear, evidence-based value narrative to support payer discussions and strengthen coverage decisions across a diagnostic portfolio.
Validated how decision-makers evaluate new diagnostic tests, clarified what evidence would drive adoption, and informed a focused strategy to support uptake at launch.
Tested and refined value propositions directly with U.S. payers to inform pricing, evidence priorities, and market access strategy ahead of launch.
Defined an early value story and evidence generation roadmap to guide clinical, HEOR, and commercial planning for a rare disease therapy under an accelerated timeline.
Aligned global and local teams to anticipate HTA challenges early, clarify disease burden and value expectations, and reduce reimbursement risk ahead of launch in HTA-driven markets.
Tested and refined value propositions directly with U.S. payers to inform pricing, evidence priorities, and market access strategy ahead of launch.
Defined an early payer value story and evidence roadmap to prioritize Phase III data generation and strengthen market access readiness ahead of launch.
Rapidly assessed the surgical complications landscape to help a large medtech company prioritize unmet needs and focus its early-stage innovation pipeline.
Supported a private equity investment decision by assessing EU reimbursement dynamics, pricing outlook, and volume trends for a diagnostics portfolio across key markets.
Developed a forward-looking value framework to help a biotech align clinical development and evidence generation with evolving payer expectations in obesity.
Clarified patient segmentation and value drivers to reduce early uncertainty and guide product planning and market access strategy.
Built a payer-ready clinical and economic value case to support U.S. coverage discussions and accelerate reimbursement decisions for an innovative medical device.
Validated a new market opportunity by clarifying patient segmentation, unmet need, and economic dynamics to support early investment and development decisions.
Developed a clear, evidence-based value narrative to support payer discussions and strengthen coverage decisions across a diagnostic portfolio.
Validated how decision-makers evaluate new diagnostic tests, clarified what evidence would drive adoption, and informed a focused strategy to support uptake at launch.
Tested and refined value propositions directly with U.S. payers to inform pricing, evidence priorities, and market access strategy ahead of launch.
Tested and refined value propositions directly with U.S. payers to inform pricing, evidence priorities, and market access strategy ahead of launch.
Helped a large diagnostics company prioritize evidence generation to strengthen its value narrative and support adoption amid increasing payer scrutiny.
Supported a private equity investment decision by assessing EU reimbursement dynamics, pricing outlook, and volume trends for a diagnostics portfolio across key markets.
Developed a forward-looking value framework to help a biotech align clinical development and evidence generation with evolving payer expectations in obesity.
Clarified patient segmentation and value drivers to reduce early uncertainty and guide product planning and market access strategy.
Validated a new market opportunity by clarifying patient segmentation, unmet need, and economic dynamics to support early investment and development decisions.
Developed a clear, evidence-based value narrative to support payer discussions and strengthen coverage decisions across a diagnostic portfolio.
Validated how decision-makers evaluate new diagnostic tests, clarified what evidence would drive adoption, and informed a focused strategy to support uptake at launch.
Tested and refined value propositions directly with U.S. payers to inform pricing, evidence priorities, and market access strategy ahead of launch.
Supported a mid-size biotech in responding to emerging real-world evidence that favored a competitor by clarifying methodological limitations, shaping the evidence narrative, and protecting long-term access and positioning.
Defined an early value story and evidence generation roadmap to guide clinical, HEOR, and commercial planning for a rare disease therapy under an accelerated timeline.
Defined an early payer value story and evidence roadmap to prioritize Phase III data generation and strengthen market access readiness ahead of launch.
Helped a large diagnostics company prioritize evidence generation to strengthen its value narrative and support adoption amid increasing payer scrutiny.
Supported a mid-size biotech in responding to emerging real-world evidence that favored a competitor by clarifying methodological limitations, shaping the evidence narrative, and protecting long-term access and positioning.
Validated a new market opportunity by clarifying patient segmentation, unmet need, and economic dynamics to support early investment and development decisions.
Tested and refined value propositions directly with U.S. payers to inform pricing, evidence priorities, and market access strategy ahead of launch.
Defined an early payer value story and evidence roadmap to prioritize Phase III data generation and strengthen market access readiness ahead of launch.
Helped a large diagnostics company prioritize evidence generation to strengthen its value narrative and support adoption amid increasing payer scrutiny.
Rapidly assessed the surgical complications landscape to help a large medtech company prioritize unmet needs and focus its early-stage innovation pipeline.
Supported a private equity investment decision by assessing EU reimbursement dynamics, pricing outlook, and volume trends for a diagnostics portfolio across key markets.
Centralized local access insights into a single, usable system to reduce duplication, accelerate launch readiness, and enable consistent payer strategies across markets.
Developed a forward-looking value framework to help a biotech align clinical development and evidence generation with evolving payer expectations in obesity.
Clarified patient segmentation and value drivers to reduce early uncertainty and guide product planning and market access strategy.
Built a payer-ready clinical and economic value case to support U.S. coverage discussions and accelerate reimbursement decisions for an innovative medical device.
Established a clear, evidence-based value narrative to support payer coverage discussions and enable access for a novel cardiac device.
Clarified and aligned the evidence base across stakeholders to support consistent value communication and accelerate adoption in an insured market.
Developed a clear, evidence-based value narrative to support payer discussions and strengthen coverage decisions across a diagnostic portfolio.
Validated how decision-makers evaluate new diagnostic tests, clarified what evidence would drive adoption, and informed a focused strategy to support uptake at launch.
Tested and refined value propositions directly with U.S. payers to inform pricing, evidence priorities, and market access strategy ahead of launch.
Defined an early value story and evidence generation roadmap to guide clinical, HEOR, and commercial planning for a rare disease therapy under an accelerated timeline.
Aligned global and local teams to anticipate HTA challenges early, clarify disease burden and value expectations, and reduce reimbursement risk ahead of launch in HTA-driven markets.